Last reviewed · How we verify

lidocaine and sufentanil

RenJi Hospital · FDA-approved active Small molecule

Lidocaine blocks sodium channels to provide local anesthesia, while sufentanil is an opioid agonist that binds to mu opioid receptors to provide analgesia and sedation.

Lidocaine blocks sodium channels to provide local anesthesia, while sufentanil is an opioid agonist that binds to mu opioid receptors to provide analgesia and sedation. Used for Local anesthesia and analgesia for medical procedures, Pain management in perioperative settings.

At a glance

Generic namelidocaine and sufentanil
SponsorRenJi Hospital
Drug classLocal anesthetic and opioid analgesic combination
TargetVoltage-gated sodium channels (lidocaine); mu opioid receptor (sufentanil)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

This is a combination product where lidocaine acts as a local anesthetic by inhibiting sodium influx in nerve fibers, preventing pain signal transmission at the site of administration. Sufentanil, a potent synthetic opioid, activates mu opioid receptors in the central and peripheral nervous system to produce analgesia, sedation, and euphoria. Together, they provide both local and systemic pain relief.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: